Verily Life Sciences
Verily Life Sciences raises $1B Series D at $6B valuation
Quick Facts
Verily Life Sciences: Series D Funding Round
Verily Life Sciences has successfully raised $1B in Series D funding, reaching a valuation of $6B.
Company Overview
Precision health and life sciences research
Funding Details
The Series D round was led by Temasek, with participation from Silver Lake, Ontario Teachers.
Company Information
- Headquarters: South San Francisco, CA
- Founded: 2015
- Employees: 1500+
- Category: HealthTech
Investment
Verily Life Sciences plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Temasek: Verified investor in Series D
- Silver Lake: Verified investor in Series D
- Ontario Teachers: Verified investor in Series D
Key Investors
About the Author
Related Company Reports
AccelerateStack Platform raises $75M Series C at $226M valuation
AccelerateStack Platform secures $75M in Series C funding led by Intel Capital, reaching $226M valuation as it accelerates growth in the healthtech sector.
DermaSensor raises $16M Series B at $85M valuation
DermaSensor raises $16M in Series B at $85M valuation. AI-powered skin cancer screening device for early detection...
Devoted Health Partners Headquarters - Office Location & Address
Discover Devoted Health Partners's headquarters at 100 2nd Ave, Waltham, MA 02451. Medicare Advantage insurance. Learn about the office facilities and work environment.
